There was always the concern that extremely stiff competition for Covid medications, especially from BPs, would steal much of ABLs thunder even if the drug proves successful. However, that does not mean all is lost.  A successful ABL trial will absolutely contribute to validating the epigenetic science behind ABL and, as DM has already stated, provide a positive lead up to BoM2.  Further, RVX is currently trading at rather dismal levels so anything that could help to boost that up to a more appropriate valuation would, to say the least, be welcome.

I recall that leading up to BoM there seemed to be a fairly high degree of confidence that the trial would be successful, and in some respects (particularly post hoc) one could argue that it has been.  It seems to me that that by partnering with Eversana and the recent collaboration with the Arab-African organization that the company fully expects this Covid trial to be successful, perhaps even more so than with BoM.  Time will tell, but no matter how you slice ita positive trial will be very beneficial at this stage even if the commercial benefits doesn't necessarily move the SP into the  lofty heights we would all like.